Gavini MP, Mahmood A, Belenchia AM, Beauparlant P, Kumar SA, Ardhanari S, DeMarco VG, Pulakat L (2021) Suppression of inflammatory cardiac cytokine network in rats with untreated obesity and pre-diabetes by AT2 receptor agonist NP-6A4. Front Pharmacol 12:693167. doi: 10.3389/fphar.2021.693167 PMID: 34220518
Objective: To determine whether NP-6A4 (a new AT2R peptide agonist with an FDA orphan drug designation for pediatric cardiomyopathy) would mitigate cardiac damage from chronic inflammation induced by untreated obesity.
Summary: Seventeen pro-inflammatory and pro-fibrotic cytokines that increase during lethal cytokine storms caused by infections such as COVID-19 were among the cytokines suppressed by NP-6A4 treatment in ZO rat heart. Thus, NP-6A4 activates a novel anti-inflammatory network comprised of 21 proteins in the heart that was not reported previously. Since NP-6A4’s unique mode of action suppresses pro-inflammatory cytokine network and attenuates myocardial damage, it can be an ideal adjuvant drug with other anti-glycemic, anti-hypertensive, standard-of-care drugs to protect the heart tissues from pro-inflammatory and pro-fibrotic cytokine attack induced by obesity.
Usage: Immunohistochemistry, 5-micrometer heart sections
Related Products: Angiotensin II receptor (AT-2R) Rabbit Polyclonal, affinity-purified (Cat. #AB-N28AP)